Abstract:DNA polymerase theta (Pol theta), also known as DNA polymerase theta, is the member of the DNA polymerase A family and plays a crucial role in the repair of DNA double-strand breaks (DSB). Pol theta has 3 distinct structural domains: the N-terminal helicase-like domain with a conserved sequence, the C-terminal polymerase domain, and the central domain, which is a disordered sequence connecting these two regions. Notably, Pol theta is the only known polymerase in eukaryotes that possesses helicase activity. However, it is also an error-prone polymerase. When DNA DSBs occur, a specialized network consisting of at least 4 pathways, including classical-non homologous end joining (C-NHEJ), homologous recombination (HR), single-strand annealing (SSA), and alternative-end joining (Alt-EJ), is responsible for repairing DNA damage caused by DSBs. In the absence of major DNA repair pathways like HR, cells rely on Alt-EJ pathway mediated by Pol theta to repair damaged DNA and maintain genomic stability. Nevertheless, due to the low fidelity of Pol theta, Alt-EJ repair often leads to errors.Depletion of Pol theta has shown to increases DSB formation and compromise genomic stability. Conversely,overexpression of Pol theta has been associated with increases DNA damage markers and impairs cell cycle progression. As a result, the impact of Pol theta on genome stability remains controversial. Furthermore,overexpression of Pol theta is frequently observed in cancer and is associated with a characteristic mutational signature and poor prognosis. Depleting Pol theta in an HR-deficient background has been shown to impair cell viability, suggesting a synthetic lethal (SL) relationship between Pol theta and HR factors. In recent years, targeted chemotherapy drugs that inhibit tumor growth have gained significant attention. However, off-target effects and drug resistance pose challenges for clinical application, particularly with poly-ADP-ribose polymerase inhibitor (PARPi). Blocking Pol theta activity in HR-deficient tumor cells has been found to reverse PARPi resistance, making Pol theta a very promising therapeutic target in cancer treatment. The availability of crystal structures for both helicase and polymerase domain has facilitated the design of potent inhibitors of Pol theta. Currently, several highly specific and effective small molecule inhibitors targeting Pol theta, such as Novobiocin, RP-6685, and ART558, have been reported to effectively block various cancers with HR deficiency. The initial success of these inhibitors points to new directions for treating BRCA1/2-mutated tumors. Additionally, reducing the Alt-EJ repair pathway mediated by Pol theta can improve HR repair efficiency and increase the chance of exogenous gene target integration (TI),suggesting potential new applications for Pol theta inhibitors. This article reviews the recent research progress on the molecular function of Pol theta and its involvement in the Alt-EJ pathway modification mechanism, providing insights for a deeper understanding of this field.

Structural basis for a Polθ helicase small-molecule inhibitor revealed by cryo-EM

Structural Basis for Pol theta-Helicase DNA Binding and Microhomology-Mediated End-Joining

Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance

Abstract 512: Identification of SS008871, a novel Polθ inhibitor that effectively inhibits tumors with homologous recombination deficiency in vitro and in vivo

Structure and Mechanism of Human DNA Polymerase Η

Early Drug Discovery and Development of Novel Cancer Therapeutics Targeting DNA Polymerase Eta (POLH)

Abstract 4532: Discovery of DAT-1000A, a potent Polθ inhibitor that significantly enhances anti-tumor efficacy in combination with PARP inhibitor in homologous-recombination-deficient tumors

Discovery and Proof of Concept of Potent Dual Polθ/PARP Inhibitors for Efficient Treatment of Homologous Recombination-Deficient Tumors

DNA Polymerase Θ: a Multifunctional and Error-prone DNA End Repair Enzyme

Discovery of 3-hydroxymethyl-azetidine derivatives as potent polymerase theta inhibitors

Human polymerase theta helicase positions DNA microhomologies for double-strand break repair

Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer

Polθ promotes the repair of 5′-DNA-protein crosslinks by microhomology-mediated end-joining

The helicase domain of Polθ counteracts RPA to promote alt-NHEJ

Abstract 671: Cryo-electronmicroscopy of PI3K Reveals Additional Regulatory Features

Talazoparib enhances resection at DSBs and renders HR-proficient cancer cells susceptible to Polθ inhibition

Polθ Inhibitor (ART558) Demonstrates a Synthetic Lethal Effect with PARP and RAD52 Inhibitors in Glioblastoma Cells

Polθ is phosphorylated by PLK1 to repair double-strand breaks in mitosis

Structural basis of DNA polymerase θ mediated DNA end joining

Abstract 7119: Clinic-ready Polθ inhibitor SYX1097 suppresses solid tumors in vivo